• Chuanxiong Cortex vs Pith in Coronary Heart Disease

  2026-10-08

  Li et al. distinguish the volatile chemical profiles and predicted pharmacological networks of Chuanxiong rhizome cortex and pith using SPME-GC×GC-MS, network pharmacology, pathway analysis, and molecular docking. The study suggests that these anatomical regions should not be treated as chemically interchangeable, while its computational findings remain hypothesis-generating rather than proof of clinical efficacy or target activation.

• Coronavirus Macrodomains and PARP-Mediated Restriction

  2026-10-08

  Grunewald et al. showed that coronavirus macrodomains counter host PARP-dependent restriction, linking ADP-ribosylation to both viral replication control and interferon induction. The study identifies PARP12 and PARP14 as important contributors in model systems while defining clear limits on how these findings should be transferred to therapeutic or nonviral research contexts.

• RBMS1 Loss and Anti-Tumor Immunity in TNBC

  2026-10-07

  The 2022 Cell Death & Differentiation study identifies RBMS1 as an RNA-binding regulator that helps immune-cold triple-negative breast cancer maintain PD-L1 stability through B4GALT1-dependent glycosylation. Its findings connect post-transcriptional RNA regulation with tumor immune escape and support further investigation of RBMS1-centered combination immunotherapy, while remaining preclinical and mechanistically focused.

• Vincristine Sulfate: Mechanism Meets Evidence

  2026-10-07

  Vincristine sulfate is a microtubule-targeting antitumor agent with a distinctive evidence profile. This article connects its molecular mechanism to cancer research interpretation while using a sumatriptan systematic review to clarify evidence strength, provenance, and translational boundaries.

• Bafilomycin C1 in Mechanism-Aware Cell Research

  2026-10-06

  Bafilomycin C1 is described by APExBIO as a vacuolar H+-ATPases inhibitor used to investigate acidic organelle biology. This overview compares its mechanistic rationale with published high-content cardiotoxicity research, emphasizing conceptual applications, evidence strength, interpretation limits, and the lack of direct Bafilomycin C1-specific findings in the supplied study.

• Tunicamycin in ER Stress and Inflammation Research

  2026-10-06

  Tunicamycin is a research-use N-glycosylation inhibitor commonly used as an endoplasmic reticulum stress inducer. This overview compares supplier-reported macrophage findings with a 2025 FASEB Journal study linking UPR-regulated ATF6 to endothelial inflammation after hepatectomy, while emphasizing model-specific evidence, mechanistic limits, and translational boundaries.

• Anti Reverse Cap Analog: Evidence and Limits

  2026-10-05

  A source-grounded overview of Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, explaining its molecular rationale, what the available evidence does and does not establish, and how an OLIG2 synthetic mRNA study should be interpreted without extending preclinical findings into clinical claims.

• Coronavirus Macrodomains and PARP-Mediated Restriction

  2026-10-05

  Grunewald and colleagues showed that coronavirus macrodomains counter a host antiviral pathway involving PARP12 and PARP14, linking ADP-ribosylation to both viral restriction and interferon regulation. The study is significant because pharmacologic and genetic evidence converged on a mechanism in which macrodomain-defective coronavirus becomes more vulnerable to PARP activity, although the findings do not establish a universal mechanism across all coronaviruses or tissues.

• LG 101506: RXR Research Context and Evidence

  2026-10-04

  A source-grounded overview of LG 101506 as a supplier-described RXR modulator, its relevance to nuclear receptor signaling, and the limits of connecting it to published triple-negative breast cancer immunotherapy findings.

• EZ Cap™ Cre mRNA (m1Ψ) Workflow Guide

  2026-10-02

  Build transient, loxP-directed recombination assays with efficiently translated Cre recombinase mRNA while preserving experimental flexibility. This guide connects product handling, delivery-platform benchmarking, extrahepatic targeting concepts, and practical troubleshooting.

• Cx43/NF-κB Signaling in AngII Macrophage Polarization

  2026-10-01

  Wu et al. showed that angiotensin II drives RAW264.7 macrophages toward a pro-inflammatory M1 phenotype through a connexin 43–NF-κB/p65 axis. Pharmacological inhibition of NF-κB or Cx43 reduced inflammatory markers, positioning Cx43 as a mechanistic contributor to AngII-associated macrophage activation and a potential target for cardiovascular inflammation research.

• Imatinib hydrochloride: Assay Workflows & Optimization

  2026-10-01

  Build more reliable kinase-driven cancer assays with a workflow that connects dose response, target engagement, and orthogonal phospho-signaling readouts. This guide also shows how recent kinase–phosphatase findings can sharpen assay interpretation without overextending evidence beyond imatinib’s validated targets.

• 3-Hydroxybutyrate (BHBA): From Metabolite to Mechanism

  2026-09-30

  3-hydroxybutyrate (BHBA) is more than a ketosis marker: it is a metabolic, membrane-active, and epigenetic research probe. This article presents an assay-centered framework for separating direct BHBA effects from broader ketone-body and ischemic-conditioning responses.

• AZD8055: Practical mTOR Inhibitor Workflow

  2026-09-30

  AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling, cancer-cell proliferation, and metabolic responses. It is appropriate for mechanistic preclinical workflows but should not be used to support clinical efficacy conclusions or protocols requiring aqueous or ethanol solubility.

• DeferoxamineB in Iron-Dependent Cancer Assays

  2026-09-29

  DeferoxamineB provides a controllable iron-chelation axis for separating iron-dependent stress from copper-associated, apoptotic, and autophagic effects in cancer models. This workflow shows how to combine dose-response testing, orthogonal cell-death readouts, and metabolic controls without mistaking chelation-based rescue for proof of a single death pathway.

8082 records 1/539 page Next 12345 下5页 Last page